Placeholder Banner

What’s In Store for Biotechs at this Year’s CEO & Investor Conference

January 17, 2014
In just a few weeks, industry leaders will gather in New York for one of BIO’s largest and most successful events, the 16th Annual BIO CEO & Investor Conference. As we’ve seen at JPMorgan, the extraordinary performance of biotech equities for the past several years has generated a great deal of interest among investors to work with biotech companies to foster innovation in the coming year. This year’s event is shaping up to be even better than last year, and company presentations are already sold out. Biotech executives can look forward to higher anticipated investor attendance, informative programming with industry predictions for 2014, and increased activity in the BIO One-on-One PartneringTM System.

More Quality Investors in Attendance

Investor registration is already up 35%, and our early projections indicate that we will have an increase in the number of registered investors over 2013. Investor registration is pacing well ahead of last year; the current list of registered investment firms can be viewed here (updated weekly). This extraordinary representation by investors means that the odds are in your favor to find a fitting partner.

Increased Requests for One-on-Ones

The CEO & Investor Conference offers biotech executives an unparalleled opportunity to connect one-on-one with investors from top global firms. These meetings allow industry executives to meet and explore business opportunities with investors in a private setting. We’re already seeing over four times as much activity in the BIO One-on-One PartneringTM System than at this point last year, indicating that both companies and investors are hungry to make deals.

Cutting-Edge Programming

This event is a rare chance to hear from industry policy experts about what effect decisions in Washington could have on your bottom line, with sessions including The Reimbursement Landscape Under ACA.  In addition to the business roundtables and therapeutic workshops, the opening and closing plenary sessions will offer a look at the state of capital markets for biotech and what that means for companies and investors in 2014. Learn why the markets are doing well and what effect it has had on the entire biotech ecosystem, and get advice on how to use this momentum to secure the capital your company needs.

We hope to see you there! If you haven’t already, be sure to register by clicking here.